In hypertensive outpatients with TIA (Fig. 2a), angiotensin-converting enzyme (ACE) inhibitors was considered the preferred first-line option by about 57% of GPs, whereas 58% of SPs clearly identified angiotensin receptor blockers (ARBs) as first line therapy. The gene discussed is ACE; the disease is transient ischemic attack.